Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | NSD2 | O96028 | 2/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teloxantrone SCHEMBL9177269 | 0.99 | TOP2A (0.69) | TOP2AMEN1USP2LMNATP53 | |
| Teloxantrone SCHEMBL3195 | 0.98 | TOP2A (0.68) | TOP2AMEN1USP2LMNATP53 | |
| Teloxantrone SCHEMBL29397399 | 0.98 | TOP2A (0.68) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10804721 | 0.96 | TOP2A (0.70) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10998300 | 0.94 | TOP2A (0.79) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10802433 | 0.91 | TOP2A (0.64) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10805640 | 0.90 | TOP2A (0.70) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10805304 | 0.90 | TOP2A (0.72) | TOP2AMEN1USP2LMNATP53 | |
| Piroxantrone SCHEMBL93599 | 0.90 | TOP2A (0.69) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10803111 | 0.90 | TOP2A (0.72) | TOP2AMEN1USP2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1082 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021069349-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | claimed |
| EP-3804701-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS PORTIONS OF AN ACTIVE SUBSTANCE | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| EP-3804702-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING ACTIVE AGENT, POLYMER AND SURFACTANT | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | claimed |
| CN-1634585-A | Anti-cancer medicine composition | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| CN-1634583-A | Anti-cancer medicine composition containing antineoplastic antibiotics | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030036794-A1 | Coated implantable medical device | COOK INCORPORATED | 2003-02-20 | — | — | US | claimed |
| EP-1085891-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| WO-1999064054-A9 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999064054-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| EP-0103381-B1 | SUBSTITUTED ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONES | WARNER-LAMBERT COMPANY (US) | 1987-09-23 | — | — | EP | claimed |
| EP-0103381-A1 | Substituted anthra(1,9-cd)pyrazol-6(2H)-ones | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | claimed |